Answers are grounded in this paper and cite their sources.
We embarked on a structural optimization campaign aimed at the discovery of novel anti‐angiogenesis agents with previously reported imidazole kinase inhibitors as a lead compound. A library of 29 compounds was synthesized. Several title compounds exhibited selective inhibitory activities against vascular endothelial growth factor receptor 2 (VEGFR‐2) over epidermal growth factor receptor (EGFR) kinase; these compounds also displayed selective and potent antiproliferative activity against three cancer cell lines. The newly synthesized compounds were evaluated for anti‐angiogenesis activity by chick chorioallantoic membrane (CAM) assay. Among them, 1‐(2‐(2‐chlorophenyl)benzo[d]oxazol‐5‐yl)‐3‐(4‐(trifluoromethoxy)phenyl)urea (compound 5 n) showed the most potent anti‐angiogenesis capacity, efficient cytotoxic activities (in vitro against human umbilical vein endothelial cells (HUVEC), H1975, A549, and HeLa cell lines, with respective IC50 values of 8.46, 1.40, 7.61, and 0.28 μm), and an acceptable level of VEGFR‐2 kinase inhibition (IC50=0.25 μm). Molecular docking analysis revealed 5 n to be a type II inhibitor of VEGFR‐2 kinase. In general, these results indicate that these 6‐arylurea‐2‐arylbenzoxazole/benzimidazole derivatives are promising inhibitors of VEGFR‐2 kinase for potential development into anti‐angiogenesis drugs.
No takes yet. Share an insight, caveat, or question.
Zi et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: